glp 1 cancer GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways Are GLP-1 Drugs Are Next
Description
Rosiglitazone monotherapy in mild-to-moderate Alzheimers disease: results from a randomized, double-blind, placebo-controlled phase III study
For colorectal cancer, current US Preventive Services Task Force guidelines recommend screening beginning at age 45 for average-risk individuals, using colonoscopy, stool-based tests, or other approved methods
The matched control group of individuals without GLP-1 RA prescriptions had a mean (SD) age of 59.3 (13.9) years and included 93 757 females (50.7%) and 91 309 males (49.3%), with 5716 individuals who identified as Asian (3.1%), 33 209 as Black or African American (17.9%), 17 693 as Hispanic (9.6%), 128 769 as not Hispanic or Latino (69.6%), and as 114 315 White (61.8%)
GLP-1 receptor agonists have been stealing the spotlight latelyand for good reason
Many treatment options focus only on managing symptoms, and some including opioids can come with serious downsides
